Pulmonary effects of dexfenfluramine
MetadataShow full item record
Dexfenfluramine is a variation of fenfluramine which is used for weight reduction. The aim of the study is to determine the hemodynamic and structural effects of this drug on pulmonary circulation. An experimental study was carried out with New Zealand Rabbits. A control group (n=30) and an experimental group (n=20) was constituted. A four-week normal diet for control group and dexfenfluramine plus normal diet for experimental group were applied. Body weights and pulmonary artery pressures of groups were recorded and lungs were collected for pathologic examination. In experimental group: Dexfenfluramine raised systolic pulmonary artery pressures significantly (p<0.01), whereas, there were no meaningful changes on diastolic and mean pulmonary artery pressures (p>0.05). Weight reduction was obvious (f= 8.522, p<0.01), in experimental group. There were marked histopathologic changes in accordance with pulmonary hypertension. In addition, squamouse metaplasia (n=1) and tumorlet (n=3) formations were seen. The use of dexfenfluramine was associated with the development of primary pulmonary hypertension. Duration and dosage relations of the therapy and topical effects of the drug should be investigated with further studies. The reasons of tumorlet formation and squamouse metaplasia must be explained with new researches.